Drug Trial Radar · NCT00286273
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
Last checked: Nov 20, 2026Latest source record: Aug 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
215
Actual
Start
Mar 2003
Primary completion
Jan 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- Onze Lieve Vrouwe GasthuisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications. Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.
Conditions
- Kidney Failure, Acute
Interventions
trisodium citrateDrug
for regional anticoagulation of the extracorporeal CVVH circuit
nadroparinDrug
for anticoagulation of the extracorporeal CVVH circuit
Primary outcomes
What the sponsor says the trial is designed to measure.
- bleeding complicationsTime frame: during administration of study anticoagulant
- transfusion requirementTime frame: during administration of study anticoagulant
- filter survivalTime frame: during hemofiltration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.